The simulation firm Entelos has expanded its collaboration with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD). The new arrangement includes multiple therapeutic areas over a five-year term. During the first year of this new agreement, Entelos will dedicate several teams of research engineers and life scientists to support specific projects using its PhysioLab platforms on behalf of J&JPRD. The big company was already using Entelos’ models to validate targets, select biomarkers and optimize clinical trials for type II diabetes, obesity and anemia.